PEGylated Proteins Market : Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2030

 

The word "PEGylation" refers to the process of altering biological molecules by covalent conjugation with polyethylene glycol (PEG), a non-toxic, non-immunogenic polymer, in order to circumvent some of the limitations of particular biopharmaceuticals. By changing the physical and chemical properties of the biological molecule, such as its conformation, electrostatic binding, and hydrophobicity, PEGylation enhances the pharmacokinetic behavior of the drug. PEGylation typically increases drug solubility while lowering immunogenicity. Along with extending the time that conjugates stay in the bloodstream, PEGylation also increases drug stability, reduces proteolysis, and increases renal excretion, all of which enable less frequent dosing.

PEGylated Proteins Market is the biochemical process of modifying bioactive molecules with polyethylene glycol (PEG), which gives proteins/peptides, antibodies, and vesicles numerous favorable qualities that are thought to be useful for therapy or cell genetic alteration.

Drug solubility is increased, and immunogenicity is reduced, by PEGylated Proteins Market. PEGylation also prolongs the period that conjugates remain in the blood, improves drug stability, and decreases proteolysis and renal excretion, all of which enable a decrease in the number of doses that must be administered.

The major market drivers include rising protein-based drug adoption over non-protein-based drugs, rising R&D spending by pharmaceutical and biotechnology companies, expansion of the biologics industry, high prevalence of lifestyle diseases, and increased protein stability and circulating half-life via PEGylation. The main obstacle impeding this market's growth, however, is drug failure and recalls.

The market sizes and growth rates of the global PEGylated Proteins Market and its subsegments were determined using a combination of bottom-up and top-down methods. All percentage splits, breakdowns, and shares were calculated using secondary sources and confirmed using primary sources.

Key Players

Thermo Fisher Scientific Inc., Horizon Therapeutics Plc., Novo Nordisk A/S, F. Hoffmann-La Roche AG, Bayer AG, BioMarin, and RedHill Biopharma Ltd. are significant players in the global PEGylated proteins market, in addition to Biogen Inc., Pfizer Inc., UCB S.A., Leadiant Biosciences, Inc., Amgen Inc., and Leadiant Biosciences, Inc.